

## 1 **Supplementary materials and methods**

### 2 **Reagents**

3 The antibodies used were as follows:

4 For western blot and immunohistochemistry, rabbit monoclonal anti-MPO antibody  
5 (Abcam, Cambridge, UK), rabbit monoclonal anti- $\alpha$ SMA antibody (Abcam,  
6 Cambridge, UK), rabbit monoclonal anti-TIPM-1 antibody (Abcam, Cambridge, UK),  
7 rabbit monoclonal anti-COL1A1 antibody (Abcam, Cambridge, UK), rabbit  
8 monoclonal anti-RAS antibody (Cell Signaling Technology, MA, USA), rabbit  
9 monoclonal anti-bRAF antibody (Cell Signaling Technology, MA, USA), rabbit  
10 monoclonal anti- phospho-bRAF antibody (Cell Signaling Technology, MA, USA),  
11 rabbit monoclonal anti-cRAF antibody (Cell Signaling Technology, MA, USA), rabbit  
12 monoclonal anti- phospho-cRAF antibody (Cell Signaling Technology, MA, USA),  
13 rabbit monoclonal anti-MEK antibody (Cell Signaling Technology, MA, USA), rabbit  
14 monoclonal anti- phospho-MEK antibody (Cell Signaling Technology, MA, USA),  
15 rabbit monoclonal anti-JNK antibody (Cell Signaling Technology, MA, USA), rabbit  
16 monoclonal anti- phospho-JNK antibody (Cell Signaling Technology, MA, USA),  
17 rabbit monoclonal anti-ERK antibody (Cell Signaling Technology, MA, USA), rabbit  
18 monoclonal anti- phospho-ERK antibody (Cell Signaling Technology, MA, USA),  
19 rabbit monoclonal anti-p38 antibody (Cell Signaling Technology, MA, USA), rabbit  
20 monoclonal anti- phospho-p38 antibody (Cell Signaling Technology, MA, USA), rabbit  
21 monoclonal anti-GAPDH antibody (Cell Signaling Technology, MA, USA), mouse  
22 monoclonal anti-GAPDH antibody (Cell Signaling Technology, MA, USA), rabbit

23 monoclonal anti-TAOK1 antibody (Thermo Fisher Scientific, MA, USA) , Mouse  
24 monoclonal anti-MAPKAPK5 antibody (Thermo Fisher Scientific, MA, USA) were  
25 used were used (i.e., all antibodies used are listed in Supplemental Table 4).

26 For immunofluorescence, rabbit monoclonal anti- $\alpha$ SMA antibody (Abcam,  
27 Cambridge, UK), mouse monoclonal anti-MPO antibody (Abcam, Cambridge, UK),  
28 rabbit monoclonal anti-H3cit antibody (Abcam, Cambridge, UK), rabbit monoclonal  
29 anti-TAOK1 antibody (Thermo Fisher Scientific, MA, USA), Rhodamine Red-X (RRX)  
30 goat anti-mouse IgG (H+L) and FITC-AffiniPure goat anti-rabbit IgG (H+L) (Jackson,  
31 PA, USA) were used.

32 For flow cytometry, freshly isolated liver nonparenchymal cells (LNPCs) were  
33 incubated with mouse Fc receptor blocker to prevent non-specific binding. Then, the  
34 cells were incubated with various staining antibodies, including APC  
35 Cyanine7conjugated anti-mouse CD45 (clone 30F11, Miltenyi Research Inc. , CA,  
36 USA), PEvio770 conjugate anti-mouse CD11b (clone M1/70, Thermo Fisher Scientific,  
37 MA, USA), APC conjugated anti-mouse F4/80 (clone BM8, Thermo Fisher Scientific,  
38 MA, USA), FITC-conjugated anti-mouse Ly6C (clone AL21, BD Biosciences, NJ,  
39 USA), PE-conjugated anti-mouse Ly6G (clone RB6-8C5, Thermo Fisher Scientific,  
40 MA, USA). In identifying the proportion of PAD4<sup>+</sup> neutrophils, the antibodies used are  
41 as follows: Alexa Fluor® 488 monoclonal anti-rabbit PAD4 (Abcam, Cambridge, UK),  
42 APC conjugated anti-mouse CD45 (clone I3/2.3, Biolegend, CA, USA), PE-conjugated  
43 anti-mouse Ly6G (clone 1A8, Biolegend, CA, USA), PerCP/Cyanine5.5 anti-mouse  
44 CD11b (M1/70, Biolegend, CA, USA).

45 The following chemicals were also utilized: IL-8 (Sigma-Aldrich, MO, USA) , G-  
46 CSF (Sigma-Aldrich, MO, USA) , TNF-beta (Sigma-Aldrich, MO, USA),  
47 Myeloperoxidase Inhibitor PF1355 (Cayman Chemical, MI, USA), ELANE Inhibitor  
48 ONO5046 (Cayman Chemical, MI, USA), DNase I (Sigma-Aldrich, MO, USA), TAO  
49 Kinase inhibitor 1 (MedChemexpress, NJ, USA), MAPK Inhibitor U0126 (Sigma-  
50 Aldrich, MO, USA).

### 51 **Cell culture**

52 Human hepatic stellate cell line LX-2 was purchased from Procell Life Science &  
53 Technology (Wuhan, China) and cultured in the complete DMEM (ATCC, VA, USA)  
54 supplemented with 10% fetal bovine serum (Hyclone, UT, USA).

### 55 **Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT)** 56 **analysis**

57 Blood was collected from the post-orbital venous plexus. The serum was separated  
58 by centrifugation and the levels of AST and ALT in the serum were measured with an  
59 automated chemical analyzer (MODULAR EVO 4200, Switzerland).

### 60 **Neutrophil isolation and in vitro NETs induction**

61 Neutrophils were isolated from peripheral blood of MASLD patients using  
62 Polymorphprep™ (Axis-Shield PoC AS, OSLO, Norway). The lysis of red blood cells  
63 was performed using a hypotonic solution (Solarbio, Beijing, China) according to the  
64 manuscript. The neutrophils ( $5 \times 10^6$  cells) seeded in 10cm culture plates were cultured  
65 in RPMI 1640 with 10% fetal bovine serum in a humidified 5% CO<sub>2</sub> incubator at 37°C.  
66 As determined by Wright staining and FACS analysis, the final neutrophil suspensions

67 contained fewer than 0.1% monocytes or lymphocytes. Neutrophil viability exceeded  
68 98% after up to 6h in culture, as determined by trypan blue exclusion and by Annexin  
69 V/propidium iodide FACS analysis. Isolated neutrophils were incubated with NETs  
70 inducers (100ng/ml IL-8, 100ng/ml G-CSF, 100ng/ml TNF-beta). Following  
71 stimulation for 6h, the supernatant was carefully discarded to remove any soluble  
72 factors released into the media. The cell culture wells were then gently washed with 2  
73 ml of cold PBS to collect the NETs structures that had adhered to the bottom surface.  
74 The PBS containing the washed-off material was then centrifuged at 1000g for 10  
75 minutes at 4°C, and the cell-free supernatant was collected as the NET preparation.

#### 76 **Detection of supernatant NETs**

77 NETs in supernatant were assayed by SYTOX Green fluorescence. SYTOX Green  
78 is a membrane-impermeable DNA-binding dye that can be used to quantify NETs-DNA.  
79 At the end of the incubation with NETs inducers, neutrophils were incubated with  
80 SYTOX Green (5µM) for 30min at 37°C. Then, after washing with PBS, NETs were  
81 observed by fluorescence microscopy.

#### 82 **Purification of NETs-DNA**

83 The NETs, previously separated, were subjected to fragmentation using a sonicator,  
84 achieving fragment sizes ranging from 200 to 500 base pairs. Following this, the DNA  
85 from these NETs was extracted and purified utilizing the MicroElute DNA Clean Up  
86 Kit (OMEGA, GA, USA).

#### 87 **Isolation of cell membrane protein**

88 Cell membrane protein of LX-2 was isolated with Mem-PER™ Plus membrane

89 protein extraction kit (Thermo Fisher Scientific, MA, USA). The procedures were  
90 according to the manufacturer's recommendation.

#### 91 **DNA-pull down**

92 NETs-DNA was biotinylated with Biotin 3' End DNA Labelling Kit (Thermo Fisher  
93 Scientific, MA, USA) according to the manufacturer's instructions. Membrane protein  
94 of LX-2 was co-cultured with 500 ng of NETs-DNA, which had been biotinylated. This  
95 reaction took place in a 400  $\mu$ l solution of IP lysis buffer (Thermo Fisher Scientific,  
96 MA, USA), and the mixture was maintained at ambient temperature for a duration of  
97 one hour. Subsequent to this, the resulting complex of protein and DNA was further  
98 treated with 50  $\mu$ l of streptavidin-agarose beads, also at room temperature, for an  
99 additional hour. Following this incubation period, the beads were subjected to a triple  
100 washing using the IP lysis buffer. The next phase involved the separation of these beads  
101 via gradient gel electrophoresis. The separation process was followed by western blot  
102 to identify specific protein bands. Lastly, these identified bands were subjected to a  
103 detailed analysis using mass spectrometry for precise identification.

#### 104 **RNA sequencing analysis (RNA-seq)**

105 RNA was extracted and subsequently converted into cDNA for the creation of a  
106 sequenced library compatible with Illumina indices. The sequencing was conducted at  
107 the Beijing Genomics Institute in China, utilizing the BGISEQ-500 system. A gene was  
108 considered to be significantly differentially expressed if it exhibited a more than  
109 twofold change in expression compared to the control, coupled with a *p* value below  
110 0.05 after adjustment. Gene Ontology was employed to analyze the heat map, with the

111 Cluster software for analysis and Java Treeview for visualization purposes. The  
112 investigation of differentially expressed genes (DEGs) involved the use of Gene  
113 Ontology tools, specifically AMIGO and DAVID. Additionally, the Kyoto  
114 Encyclopedia of Genes and Genomes annotations was utilized to assess the enrichment  
115 levels of these DEGs.

### 116 **Bone Marrow-Derived Neutrophil (BMDN) Culture and Adoptive Transfer**

117 Bone marrow cells were harvested from the femurs and tibias of mice by flushing  
118 with PBS using 25-gauge needles. The resulting cell suspension was gently dissociated  
119 and passed through a 40  $\mu\text{m}$  cell strainer to obtain a single-cell suspension. Red blood  
120 cells were lysed using RBC lysis buffer. To block GM-CSF signaling, anti-mouse GM-  
121 CSF antibody (BioLegend, #505401) was added to the culture. Neutrophils were then  
122 purified using the MojoSort™ Mouse Ly6G Selection Kit (BioLegend, #480124) and  
123 designated as bone marrow-derived neutrophils (BMDNs) for downstream applications.

124 For adoptive transfer experiments, purified BMDNs from PAD4<sup>+/+</sup> and PAD4 $\Delta$ PMN  
125 mice were counted using Trypan Blue exclusion and resuspended at a concentration of  
126  $1 \times 10^8$  viable cells/mL. Recipient mice were intravenously injected with  $1 \times 10^7$  BMDNs  
127 (in 100  $\mu\text{L}$  PBS) per mouse at designated time points. Starting from week 6 of the  
128 WD/CCl<sub>4</sub> dietary model, BMDNs were administered weekly via tail vein injection. For  
129 leukocyte quantification, peripheral blood was collected into EDTA-containing tubes,  
130 and leukocytes were stained and analyzed by flow cytometry.

### 131 **Western blot assay**

132 The expression of the indicated proteins was assayed using western blot. The  
133 indicated molecules for the analyses were listed in the Reagents. The relative levels  
134 were normalized against GAPDH in the same samples.

#### 135 **Enzyme-linked immunosorbent assay**

136 ELISA (Invitrogen, CA, USA) was applied to measure CXCL1, CXCL2, CXCL3,  
137 CXCL5, CXCL6 and CXCL8 levels in the liver of MASL and MASH patients. Each  
138 experiment was repeated in triplicates.

#### 139 **Luminex Assay**

140 Using Luminex technology, we analyzed the expression of various factors in liver  
141 samples. For every 10 mg of tissue, 200  $\mu$ L of pre-cooled lysis buffer was added. The  
142 tissue was homogenized using a tissue homogenizer, and the supernatant was collected  
143 after centrifugation. According to the instructions of the kit (Bio-Rad Laboratories, CA,  
144 USA), beads, standards, quality controls, and samples were sequentially added in  
145 volumes of 25-50  $\mu$ L and incubated at room temperature at 800 rpm for 0.5-1 hour or  
146 overnight at 4°C. Beads were then washed three times with 100-200  $\mu$ L of wash buffer.  
147 Next, 25-50  $\mu$ L of detection antibodies were added and incubated at room temperature  
148 at 800 rpm for 0.5-1 hour. The beads were washed again three times with 100-200  $\mu$ L  
149 of wash buffer, followed by the addition of 50  $\mu$ L of PE-streptavidin and incubation at  
150 room temperature at 800 rpm for 10-30 minutes. After three more washes with 100-200  
151  $\mu$ L of wash buffer, 100-150  $\mu$ L of sheath fluid/wash buffer was added and incubated at  
152 room temperature at 800 rpm for 0.5-2 minutes before proceeding with the analysis on  
153 the machine.

154 **Immunofluorescence**

155 Samples embedded in paraffin were sectioned to a thickness of 4 micrometers.  
156 Antigen retrieval was performed in a pressure cooker using 0.01M citrate buffer for a  
157 duration of 20 minutes. Subsequently, the sections were subjected to a blocking process  
158 using PBS supplemented with 10% bovine serum albumin at ambient temperature for  
159 two hours. Following the blocking step, the samples were incubated with primary  
160 antibodies at 4 °C throughout the night. This was followed by a one-hour room  
161 temperature incubation with Rhodamine Red-X (RRX) goat anti-mouse IgG (H+L) and  
162 FITC-AffiniPure goat anti-rabbit IgG (H+L) (Jackson ImmunoResearch Laboratories,  
163 PA, USA). For nuclear staining, DAPI (Sigma-Aldrich, MO, USA) was employed.  
164 Confocal microscopy images were captured using the Zeiss LSM510 system  
165 (Oberkochen, Germany).

166 **Immunohistochemistry**

167 The expression of MPO in the liver was detected by immunohistochemistry (IHC).  
168 IHC was applied on paraffin-embedded formalin-fixed tissue samples according to  
169 standard protocols.

170 **LC-MS/MS analysis**

171 In this analysis, tryptic peptides were reconstituted in solvent A, consisting of 0.1%  
172 formic acid, and then applied to a custom-made analytical column with a reversed-  
173 phase configuration (75 µm internal diameter, 15 cm length). We implemented a  
174 gradient elution program using solvent B (0.1% formic acid in 98% acetonitrile) that  
175 gradually increased from 6% to 23% over 26 minutes, followed by a rise to 35% in the

176 next 8 minutes, and finally peaking at 80% for the concluding 3 minutes. This elution  
177 was carried out at a steady flow rate of 400 nL/min using an EASY-nLC 1000 UPLC  
178 system. Post-column, the peptides were introduced to a nano-electrospray ionization  
179 (NSI) source and then analyzed via tandem mass spectrometry on a Q Exactive<sup>TM</sup> Plus  
180 (Thermo) system, integrated online with the UPLC. An electrospray voltage of 2.0 kV  
181 was applied. The mass-to-charge (m/z) scan range spanned from 350 to 1800 for a  
182 comprehensive scan, capturing intact peptides in the Orbitrap at a resolution of 70,000.  
183 For MS/MS, peptides were selected under a normalized collision energy (NCE) setting  
184 of 28, with their fragments detected at a 17,500 resolution in the Orbitrap. The system  
185 followed a data-dependent approach alternating between a singular MS scan and 20  
186 MS/MS scans, incorporating a 15.0 s dynamic exclusion period. The automatic gain  
187 control (AGC) threshold was set to 5E4, and the fixed first mass was established at 100  
188 m/z.

### 189 **Flow cytometry**

190 Isolated liver non-parenchymal cells (LNPCs) initially underwent treatment with a  
191 blocker for mouse Fc receptors to mitigate unspecific bindings. Subsequently, these  
192 cells were exposed to a range of fluorescently labeled antibodies for staining. The  
193 antibodies used were listed in the Reagents.

### 194 **scRNA-seq quality control, dimension-reduction and clustering (Scanpy)**

195 Scanpy v1.8.1 was used for quality control, dimensionality reduction and clustering  
196 under Python 3.7. For each sample dataset, we filtered expression matrix by the  
197 following criteria: 1) cells with gene count less than 200 or with top 2% gene count

198 were excluded; 2) cells with top 2% UMI count were excluded; 3) cells with  
199 mitochondrial content > 30% were excluded; 4) genes expressed in less than 5 cells  
200 were excluded. After filtering, 67763 cells were retained for the downstream analyses,  
201 with on average 1381.502 genes and 3938.929 UMIs per cell. The raw count matrix  
202 was normalized by total counts per cell and logarithmically transformed into  
203 normalized data matrix. Top 2000 variable genes were selected by setting flavor =  
204 'seurat'. Principal Component Analysis (PCA) was performed on the scaled variable  
205 gene matrix, and top 20 principal components were used for clustering and dimensional  
206 reduction. Cells were separated into 25 clusters by using Louvain algorithm and setting  
207 resolution parameter at 1.2. Cell clusters were visualized by using Uniform Manifold  
208 Approximation and Projection (UMAP) (1).

#### 209 **Batch Effect removal**

210 Harmony: Batch effect between samples was removed by Harmony v1.0 using the  
211 top 20 principal components from PCA (2).

#### 212 **Differentially expressed genes (DEGs) analysis (scanpy)**

213 To identify differentially expressed genes (DEGs), we used the  
214 scanpy.tl.rank\_genes\_groups function based on Wilcoxon rank sum test with default  
215 parameters, and selected the genes expressed in more than 10% of the cells in either of  
216 the compared groups of cells and with an average log(Fold Change) value greater than  
217 0.25 as DEGs. Adjusted p value was calculated by benjamini-hochberg correction and  
218 the value 0.05 was used as the criterion to evaluate the statistical significance.

#### 219 **Pathway enrichment analysis**

220 To investigate the potential functions of DEGs between neutrophils in MASH and  
221 MASL, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG)  
222 analysis were used with the “clusterProfiler” R package v 4.0.2 (3). Pathways with  
223 p\_adj value less than 0.05 were considered as significantly enriched. Selected  
224 significant pathways were plotted as lollyplot. GSEA was performed on Neutrophils'  
225 DEGs between MASH and MASL. For GSEA pathway enrichment analysis, the  
226 average gene expression of each cell type was used as input data (4). Gene Ontology  
227 gene sets including molecular function (MF), biological process (BP), and cellular  
228 component (CC) categories were used.

#### 229 **Celltype annotation, Cell-type recognition with Cell-ID**

230 Cell-ID is multivariate approach that extracts gene signatures for each individual cell  
231 and perform cell identity recognition using hypergeometric tests (HGT).  
232 Dimensionality reduction was performed on normalized gene expression matrix  
233 through multiple correspondence analysis, where both cells and genes were projected  
234 in the same low dimensional space. Then a gene ranking was calculated for each cell to  
235 obtain most featured gene sets of that cell. HGT were performed on these gene sets  
236 against liver reference from SynEcoSys database, which contains all cell-type's featured  
237 genes. Identity of each cell was determined as the cell-type has the minimal HGT p  
238 value. For cluster annotation, Frequency of each cell-type was calculated in each cluster,  
239 and cell-type with highest frequency was chosen as cluster's identity (5).

240 The cell type identification of each cluster was determined according to the expression  
241 of canonical markers from the reference database SynEcoSys<sup>TM</sup> (Singleron

242 Biotechnology). SynEcoSys™ contains collections of canonical cell type markers for  
243 single-cell seq data, from CellMakerDB, PanglaoDB and recently published literatures.

#### 244 **Subtyping of major cell types**

245 To obtain a high-resolution map of MPs, T and NK, Neutrophils cells, the specific  
246 cluster were extracted and reclustered for more detailed analysis following the same  
247 procedures described above and by setting the clustering resolution as 1.2, 1.2, 0.2  
248 respectively.

#### 249 **Cell-cell interaction analysis: CellPhoneDB**

250 Cell-cell interaction (CCI) between Neutrophils and other cell types were predicted  
251 based on known ligand–receptor pairs by Cellphone DB (v 4.0.0) version (6).  
252 Permutation number for calculating the null distribution of average ligand-receptor pair  
253 expression in randomized cell identities was set to 1000. Individual ligand or receptor  
254 expression was thresholded by a cutoff based on the average log gene expression  
255 distribution for all genes across each cell type. Predicted interaction pairs with p value  
256  $<0.05$  and of average log expression  $> 0.1$  were considered as significant and visualized  
257 by heatmap\_plot and dot\_plot in CellphoneDB.

#### 258 **Pseudotime Trajectory Analysis: monocle2**

259 Cell differentiation trajectory of monocyte subtypes was reconstructed with the  
260 Monocle2 v 2.10.0 (7). For constructing the trajectory, top 2000 highly variable genes  
261 were selected by Seurat (v3.1.2) FindVairableFeatures, and dimension-reduction was  
262 performed by DDRTree. The trajectory was visualized by plot\_cell\_trajectory function  
263 in Monocle2.

## 264 **UCell Gene Set Scoring**

265 Gene set scoring was performed using the R package UCell v 2.2.0 (8). UCell scores  
266 are based on the Mann-Whitney U statistic by ranking query genes in order of their  
267 expression levels in individual cells. Because UCell is a rank-based scoring method, it  
268 is suitable to be used in large datasets containing multiple samples and batches.

269 The NETs formation gene signature was defined based on previously published  
270 NETs-associated gene sets(9). The signature includes canonical NETs-related genes  
271 such as: PAD4, ELANE, MPO, H3F3B, TLR9, CTSG, LTF, GSDMD, and others  
272 involved in chromatin decondensation and NETs extrusion.

273 For analysis, we used: Seurat (v4.3) AddModuleScore function to calculate NETs  
274 gene signature scores in each neutrophil cluster (scRNA-seq data). Scores were  
275 compared between groups using Wilcoxon rank-sum test. Visualization in dot plots  
276 shows differential NETs scores across neutrophil subsets.

## 277 **scGSVA**

278 To do GSVA analysis for single cell data, we use scGSVA  
279 (<https://github.com/guokai8/scGSVA>), which make use of ssgsea methods to score  
280 individual cells respectively to generate multiple pathway enrichment score matrices.  
281 Using package of Limma to calculate the differential enrichment score for pathway,  
282 which absolute value of t greater than 1.96 as significant difference, among cell types.

## 283 **Transcription factor regulatory network analysis (pySCENIC)**

284 Transcription factor network was constructed by pycenic (v0.11.0) using scRNA




285 expression matrix and transcription factors in AnimalTFDB (10). First, GRNBoost2  
286 predicted a regulatory network based on the co-expression of regulators and targets.  
287 CisTarget was then applied to exclude indirect targets and to search transcription factor  
288 binding motifs. After that, AUCell was used for regulon activity quantification for every  
289 cell. Cluster-specific TF regulons were identified according to Regulon Specificity  
290 Scores (RSS) and the activity of these TF regulons were visualized in heatmaps.





291





## 292 Reference:

- 293 1. Wolf FA, Angerer P, and Theis FJ. SCANPY: large-scale single-cell gene expression data  
294 analysis. *Genome Biol.* 2018;19(1):15.
- 295 2. Butler A, Hoffman P, Smibert P, Papalexi E, and Satija R. Integrating single-cell  
296 transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol.*  
297 2018;36(5):411-20.
- 298 3. Yu G, Wang LG, Han Y, and He QY. clusterProfiler: an R package for comparing biological  
299 themes among gene clusters. *OMICS.* 2012;16(5):284-7.
- 300 4. Hanzelmann S, Castelo R, and Guinney J. GSEA: gene set variation analysis for microarray  
301 and RNA-seq data. *BMC Bioinformatics.* 2013;14:7.
- 302 5. Cortal A, Martignetti L, Six E, and Rausell A. Gene signature extraction and cell identity  
303 recognition at the single-cell level with Cell-ID. *Nat Biotechnol.* 2021;39(9):1095-102.
- 304 6. Efremova M, Vento-Tormo M, Teichmann SA, and Vento-Tormo R. CellPhoneDB:  
305 inferring cell-cell communication from combined expression of multi-subunit ligand-  
306 receptor complexes. *Nat Protoc.* 2020;15(4):1484-506.
- 307 7. Qiu X, Hill A, Packer J, Lin D, Ma YA, and Trapnell C. Single-cell mRNA quantification  
308 and differential analysis with Census. *Nat Methods.* 2017;14(3):309-15.
- 309 8. Andreatta M, and Carmona SJ. UCell: Robust and scalable single-cell gene signature  
310 scoring. *Comput Struct Biotechnol J.* 2021;19:3796-8.
- 311 9. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. *Nat Rev*  
312 *Immunol.* 2018;18(2):134-47.
- 313 10. Van de Sande B, Flerin C, Davie K, De Waegeneer M, Hulselmans G, Aibar S, et al. A  
314 scalable SCENIC workflow for single-cell gene regulatory network analysis. *Nat Protoc.*  
315 2020;15(7):2247-76.


316









A




B













C

















D











1 **Supplementary Figures**

2 Supplementary Fig. 1. **Effects of neutrophil depletion on liver under HFD and**  
3 **WD/CCl<sub>4</sub> model.** (A) To deplete neutrophils, mice were administered anti-Ly6G  
4 antibody intraperitoneally each day during the latter phase of the dietary regimen. The  
5 control group received an equivalent dose of IgG2a. (B-C) Flow cytometry was used to  
6 analyze the clearance efficiency of neutrophils (CD11b<sup>+</sup> Ly6G<sup>+</sup> populations) in the liver  
7 of each group of mice, after intraperitoneal injection of Ly6G antibody. Data are  
8 presented as mean ± SEM, based on five independent experiments. Statistical analyses  
9 were performed using two-tailed Student Test. Error bars represent mean ± SEM.

10

11 Supplementary Fig. 2. **ScRNA-seq analysis revealed differences in the proportions**  
12 **of non-parenchymal cell subsets in MASL and MASH livers.** (A) Uniform manifold  
13 approximation and projection (UMAP) analysis of non-parenchymal cells from human  
14 MASL (n=6) and MASH (n=6) livers, with each cell colored by its tissue origin. (B)  
15 Dot plot illustrating the expression of canonical marker genes across the nine major cell  
16 clusters. Dot size indicates cell proportion, while color intensity reflects standardized  
17 expression levels. (C) UMAP visualization of transcriptional profiles from 121,020  
18 non-parenchymal cells, partitioned into distinct clusters represented by different colors.  
19 (D) Bar plots showing the proportion of non-parenchymal cell subpopulations in human  
20 MASL and MASH livers.

21

22 Supplementary Fig. 3. **ScRNA-seq reveals neutrophil heterogeneity in human**  
23 **MASL and MASH liver.** (A) Dot plot illustrating the expression of canonical marker  
24 genes across the six major cell clusters of myeloid cells. Dot size indicates cell

25 proportion, while color intensity reflects standardized expression levels. (B) Volcano  
26 plot showing differentially expressed genes between neutrophils in MASH and MASL,  
27 with significance defined as  $FDR < 0.01$  and  $|\logFC| > 2$ . (C) Gene Ontology (GO)  
28 analysis of downregulated genes in MASH versus MASL, highlighting their associated  
29 molecular functions, cellular components, and biological processes. (D) GO analysis of  
30 upregulated genes in MASH versus MASL, describing the relevant molecular  
31 functions, cellular components, and biological processes.

32

33 **Supplementary Fig. 4. Functional enrichment of neutrophil subclusters by single-**  
34 **cell RNA-seq.** (A) Proportion of five neutrophil subpopulations in MASL and MASH  
35 groups. (B) Heatmap of significant KEGG pathway terms across neutrophil subtypes  
36 ( $FDR < 0.05$ ). (C) Gene Ontology Biological Process analysis for the Neut-5  
37 subpopulation ( $FDR < 0.05$ ). (D) Flow cytometry analysis of  $PAD4^+$  neutrophils from  
38 livers of HFD-fed mice.

39

40 **Supplementary Fig. 5. Inflammation-related cytokines in liver tissues from MASL**  
41 **and MASH patients.** (A-E) Luminex assay quantification of inflammation-related  
42 cytokines in liver tissues from MASL (n=10) and MASH (n=10) patients. Statistically  
43 significant cytokines are highlighted. The above cytokines had no statistical difference  
44 between the two groups. Statistical analyses were performed using two-tailed Student  
45 Test. Error bars represent mean  $\pm$  SEM.

46

47 **Supplementary Fig. 6. Effects of Inhibiting PAD4<sup>+</sup> neutrophil and NETs formation**  
48 **on liver under CD, HFD, WD/CCl<sub>4</sub> model.** (A) Schematic representation elucidates  
49 the construction of PAD4ΔPMN mice model (Created with BioRender.com). (B)  
50 Weekly monitored body weight of CD, HFD and WD/CCl<sub>4</sub> treated PAD4ΔPMN mice  
51 (10 mice/group). (C) qRT-PCR analysis of PAD4 mRNA levels in tissues of 6–8-wk-  
52 old male PAD4ΔPMN mice and PAD4<sup>+/+</sup> mice (n = 5 mice per group). Neutrophils,  
53 macrophages, monocytes were isolated from peripheral blood by positive selection  
54 using anti-Ly6G, anti-F4/80, anti-Ly6C microbeads, respectively. (D) Neutrophil  
55 counts in peripheral blood of PAD4ΔPMN mice and PAD4<sup>+/+</sup> mice (n = 5 mice per  
56 group). (E) Representative immunofluorescence images of H3Cit and MPO staining  
57 in livers from WD/CCl<sub>4</sub>-fed PAD4ΔPMN and PAD4<sup>+/+</sup> mice. NETs are identified by  
58 co-staining with H3Cit, MPO, and DAPI, Scale bars, 20 μm. (F) Representative liver  
59 sections showing phenotypic changes, lipid accumulation, and fibrosis, assessed by  
60 Masson staining after bone marrow-derived neutrophils (BMDNs) adoptive cell  
61 transfer separately. Scale bars, 50 μm. (G) Fibrosis stage of each group. Statistical  
62 analyses were performed using two-tailed Student Test. Error bars represent mean ±  
63 SEM.

64

65 **Supplementary Fig. 7. PAD4<sup>+</sup> neutrophils promote hepatic stellate cell activation**  
66 **via NETs formation and MAPK Pathway activation.** (A) Quantitative grayscale  
67 analysis of TIMP-1 protein bands from western blots. (B) Quantitative grayscale  
68 analysis of COL1A1 protein bands from western blots. (C) Volcano plot showing

69 differentially expressed genes after NETs stimulated LX-2 cells, with significance  
70 defined as  $FDR < 0.01$  and  $|\logFC| > 2$ . (D) GO analysis of differentially expressed  
71 genes, describing the relevant biological processes. (E) Quantitative grayscale analysis  
72 of phosphorylated JNK and JNK bands from western blotting. (F) Quantitative  
73 grayscale analysis of phosphorylated ERK and ERK bands from western blotting. (G)  
74 Quantitative grayscale analysis of phosphorylated p38 and p38 bands from western  
75 blots. Statistical analyses were performed using two-tailed Student Test. Error bars  
76 represent mean  $\pm$  SEM.

77

78 **Supplementary Fig. 8. Analyzing the role of NETs-DNA and TAOK1 in MAPK**  
79 **pathway activation.** (A) Quantitative grayscale analysis of phosphorylated JNK and  
80 JNK bands, phosphorylated ERK and ERK bands, phosphorylated p38 and p38 bands  
81 from western blot after adding PF1355, ONO5046, and DNase I. (B) Schematic  
82 representation of the NETs-DNA pull-down assay methodology used to identify  
83 proteins interacting with NETs-DNA. (C) LC/MS was used to detect LX-2 cell  
84 membrane proteins obtained by DNA pull down analysis, depicted in a Venn diagram.  
85 (D) A heatmap displays the top 20 proteins identified through DNA pull-down assays.  
86 (E) Quantitative grayscale analysis of TAOK1 and MAPKAPK5 bands from western  
87 blotting. (F) Quantitative grayscale analysis of  $\alpha$ -SMA, TIMP-1, phosphorylated JNK  
88 and JNK bands, phosphorylated ERK and ERK bands, phosphorylated p38 and p38  
89 bands from western blot after adding TAO Kinase inhibitor I. (G) Serum PAI-1 levels  
90 (ng/mL) measured by ELISA in WD/ $CCl_4$ -fed  $PAD4^{+/+}$  and  $PAD4\Delta PMN$  mice.

- 91 Statistical analyses were performed using one-way ANOVA and two-tailed Student
- 92 Test. Error bars represent mean  $\pm$  SEM.

93 **Supplementary Table 1. Characteristics of subjects whose Liver biopsy tissues were analyzed.**

Variables	non-MASLD (n=63)	non-MASH (n=77)	MASH (n=125)	p Value
<b>Demographic parameters</b>				
Age (years)	35 (27, 44)	31 (26, 38)	30 (25, 37)	0.021
Female (n, %)	53, 84.13	56, 72.73	87, 69.60	0.097
BMI (kg/m <sup>2</sup> )	35.50 (32.20, 40.70)	36 (32.15, 42.55)	38.50 (34.75, 44.81)	0.007
<b>Metabolic parameters</b>				
ALT (U/L)	22.50 (17.30, 29.50)	30.00 (20.40, 49.50)	49.90 (32.95, 73.65)	0.000
AST (U/L)	19.70 (17.30, 25.80)	24.50 (18.90, 34.20)	30.80 (23.60, 41.70)	0.000
GGT (U/L)	25.40 (18.50, 51.70)	34.10 (23.00, 56.85)	40.80 (27.70, 60.20)	0.001
TbiL (U/L)	10.00 (7.20, 12.90)	10.70 (7.45, 12.30)	9.90 (7.50, 12.60)	0.969
ALB(g/L)	40.07±3.44	40.81±3.66	40.78±4.05	0.420
TG (mmol/L)	4.62 (4.14, 5.27)	4.99 (4.17, 5.77)	4.90 (4.18, 5.61)	0.379
TC (mmol/L)	1.26 (0.98, 1.76)	1.64 (1.26, 2.26)	1.57 (1.18, 2.30)	0.001
HDL-C (mmol/L)	1.15 (0.92, 1.32)	1.02 (0.87, 1.23)	1.04 (0.92, 1.18)	0.059
LDL-C (mmol/L)	2.93 (2.55, 3.35)	3.16 (2.58, 3.82)	3.10 (2.60, 3.61)	0.256
<b>Liver histopathologic characteristics</b>				
Neutrophil count (n, per high-power field)	2 (1, 4)	5 (3, 11)	7 (5, 12)	0.000

94

95

96

**Supplementary Table 2. Liver histopathologic characteristics of the study individuals**

<b>Liver histopathologic characteristics</b>	<b>Total patients (n=265)</b>
<b>Steatosis, n (%)</b>	
0	63 (23.8)
1	94 (35.5)
2	75 (28.3)
3	33 (12.5)
<b>Ballooning, n (%)</b>	
0	19 (7.2)
1	96 (36.2)
2	150 (56.6)
<b>Lobular inflammation, n (%)</b>	
0	27 (10.2)
1	94 (35.5)
2	127 (47.9)
3	17 (6.4)
<b>Fibrosis, n (%)</b>	
0	24 (9.1)
1	93 (35.1)
2	86 (32.5)
3	59 (22.3)
4	3 (1.1)
<b>NAS, n (%)</b>	
<3	40 (15.09)
3-4	98 (36.98)
>4	127 (47.92)

**Supplementary Table 3. Absolute liver tissue cytokine concentrations(pg/ml) by group.**

cyt oki ne	MA SH 1	MAS H2	MA SH3	MA SH4	MA SH5	MA SH6	MA SH7	MA SH8	MA SH9	MA SH1 0	MA SL1	MA SL2	MA SL3	MA SL4	MA SL5	MA SL6	MA SL7	MA SL8	MA SL9	MA SL1 0
IL- 2R alp ha	30. 92	27.20	34.1 5	33.9 2	26.9 7	40.5 5	42.3 7	35.0 7	33.6 9	31.8 5	37.3 6	24.8 6	22.9 9	36.9 1	33.6 9	26.2 7	29.5 3	28.1 4	31.8 5	27.4 4
MI G	977 .60	2429. 00	916. 87	793. 81	525. 52	2161 .00	4377 .00	1469 .00	1587 .00	1109 .00	420. 75	507. 84	1283 .00	367. 84	575. 95	633. 05	355. 39	334. 70	1976 .00	302. 15
MI P- 1be ta	559 .56	251.2 2	169. 11	228. 30	300. 54	233. 97	224. 36	129. 52	114. 18	130. 69	149. 04	121. 01	115. 16	101. 33	77.5 7	134. 92	83.0 7	179. 43	242. 84	118. 47
IL- 6	21. 94	6.00	8.72	16.6 5	7.45	9.60	7.19	6.00	7.99	7.85	14.0 0	11.8 9	3.70	10.3 4	5.87	4.20	3.95	33.3 1	6.79	7.05
IFN - alp ha2	31. 51	19.44	23.1 3	27.5 9	25.7 5	36.8 1	38.1 4	28.6 7	33.2 5	31.8 6	33.5 9	27.5 9	22.3 6	43.0 0	33.7 6	28.8 5	26.1 2	35.4 7	25.3 8	36.4 8
IFN - ga mma	148 .40	183.1 4	184. 50	186. 99	155. 31	205. 71	211. 09	203. 46	216. 47	183. 14	194. 67	188. 12	171. 33	213. 34	191. 51	178. 38	184. 28	174. 51	181. 33	186. 77
SD F- lal pha	229 .56	562.7 5	209. 72	214. 56	448. 64	444. 62	249. 57	331. 83	364. 45	476. 06	353. 65	222. 78	269. 14	274. 29	267. 20	294. 00	153. 98	261. 36	424. 42	307. 16
IL- 1ra	925 5.0 0	1983 7.00	1885 6.00	1812 8.00	1337 9.00	2088 7.00	1832 0.00	1993 2.00	2050 8.00	1314 6.00	1835 8.00	1694 6.00	1286 9.00	1519 9.00	1670 3.00	1726 2.00	2122 4.00	1110 8.00	1559 3.00	1395 0.00
MC	4.8	5.34	5.12	5.79	4.67	6.67	6.45	5.79	5.34	5.90	5.90	4.21	4.67	6.45	4.44	4.89	4.44	3.76	5.79	5.12

P-3		9																				
IL-16		2015.000	2555.00	1944.00	3050.00	1993.00	2732.00	2757.00	2862.00	2165.00	1769.00		3091.00	2483.00	2536.00	1754.00	1692.00	2071.00	2051.00	1922.00	2463.00	1157.00
IL-12p40		213.56	377.07	332.95	264.56	189.49	315.19	315.19	332.95	344.75	344.75		285.46	183.47	243.60	294.40	243.60	207.54	201.53	183.47	261.57	177.45
LIF		69.31	77.88	85.35	94.89	54.25	73.60	94.89	77.88	71.46	65.02		80.02	58.56	56.40	80.02	66.09	54.25	62.87	51.01	75.74	49.93
TNF-beta		532.94	403.15	386.10	340.05	462.35	402.90	347.42	349.63	255.72	323.40		353.33	232.73	303.46	287.97	170.04	421.86	222.69	385.10	445.34	331.71
IL-5		134.14	138.86	181.71	142.41	160.21	118.90	214.15	223.79	216.56	170.94		182.91	175.73	150.70	268.46	279.33	186.51	147.14	187.71	161.40	231.03
GM-CSF		17.02	16.21	20.15	19.99	18.41	20.64	27.45	18.24	27.25	21.90		22.19	20.85	18.91	24.58	37.50	20.44	18.91	20.64	21.01	23.91
TNF-alpha		55.21	44.50	49.89	48.10	45.58	58.02	59.07	49.53	52.38	50.24		52.38	45.94	38.68	57.32	48.10	44.86	38.31	47.38	46.66	52.73
RANTES		587.0	1867.00	1285.00	1026.00	2090.00	1207.00	1013.00	950.18	593.09	814.86		1159.00	538.49	805.94	647.43	349.79	1195.00	507.11	1188.00	1775.00	756.12
IL-2		8.94	9.53	10.33	11.74	8.75	11.54	13.58	11.54	11.54	11.14		12.76	7.58	7.96	13.58	9.93	8.94	10.33	8.75	9.73	10.73
IL-1beta		11.81	11.48	12.49	14.57	11.90	12.95	14.74	11.98	13.41	12.32		13.91	10.97	10.21	15.90	11.94	10.72	11.98	12.82	12.65	11.65
IL-18		99.55	627.36	189.79	208.68	101.92	156.77	168.24	147.19	150.50	137.99		199.88	225.24	152.35	195.20	140.93	179.18	147.19	151.42	338.62	124.41
Eot		10.	19.69	10.3	10.5	14.1	19.4	17.7	15.7	17.8	19.4		15.4	12.6	15.0	16.9	14.2	17.4	10.5	15.5	16.4	16.0

axi n		94		1	8	3	9	0	4	0	4		8	7	1	8	9	9	2	3	6	0
Bas ic FG F		262 .73	180.2 7	441. 11	524. 47	191. 99	102. 93	567. 07	433. 06	185. 33	171. 16		433. 68	336. 31	277. 50	408. 32	374. 72	306. 32	442. 35	190. 08	464. 61	118. 67
VE GF		155 .14	183.5 7	197. 17	215. 02	172. 43	213. 75	209. 95	231. 95	242. 47	242. 47		248. 00	188. 13	147. 06	308. 28	186. 83	207. 41	186. 83	213. 75	211. 22	221. 32
beta - NG F		25. 26	18.12	26.0 3	29.9 0	25.7 7	33.4 9	39.0 9	28.8 7	37.4 4	28.3 6		37.0 6	29.1 3	14.8 8	45.1 4	32.4 7	27.4 5	22.8 0	37.0 6	26.8 1	37.0 6
PD GF- BB		286 .34	238.8 4	175. 48	219. 26	190. 84	303. 49	312. 04	299. 21	339. 72	337. 60		288. 49	219. 26	247. 51	358. 79	260. 49	294. 92	190. 84	249. 68	260. 49	337. 60
IP- 10		803 .19	2835. 00	490. 25	1213 .00	786. 21	2194 .00	2186 .00	1492 .00	1046 .00	897. 96		606. 10	834. 22	1107 .00	180. 59	601. 89	613. 63	235. 50	259. 04	1192 .00	248. 99
IL- 13		7.6 5	4.77	5.18	6.25	7.10	9.39	8.55	7.25	10.3 3	9.15		8.95	6.65	5.33	10.3 3	8.00	7.45	5.33	8.85	5.79	11.8 4
IL- 4		3.6 6	3.46	3.26	3.79	3.19	4.05	4.37	4.05	3.59	3.56		3.88	3.16	2.99	4.30	3.49	2.92	3.39	3.12	3.52	2.99
MC P-1		95. 48	79.39	56.7 2	140. 79	51.0 4	67.7 8	60.0 6	54.0 9	60.6 7	53.4 6		41.8 4	57.5 9	42.1 1	71.5 5	55.1 0	39.6 6	38.8 4	180. 61	52.4 4	57.1 0
IL- 8		59. 01	39.72	37.8 5	33.9 5	28.9 0	26.2 5	11.7 0	20.0 6	11.6 1	11.6 1		11.3 5	10.5 6	10.0 4	9.69	8.83	8.48	6.08	26.0 7	16.0 0	12.3 1
MI P- lal pha		144 .46	45.01	45.8 8	67.4 4	53.9 0	68.6 0	43.6 9	19.7 4	37.4 1	17.0 6		24.6 4	26.2 2	12.4 8	20.6 8	18.8 4	13.4 2	8.74	45.3 9	37.0 5	22.8 0
IL- 10		26. 77	19.64	30.9 4	37.4 9	28.5 6	56.1 2	48.1 6	41.9 5	50.8 2	50.5 2		36.9 0	35.1 1	32.1 4	54.9 4	54.0 6	35.7 1	24.9 9	46.9 8	27.9 7	48.1 6
G- CS		326 6.0	1362. 00	1357 .00	1915 .00	1567 .00	1919 .00	1385 .00	985. 65	1376 .00	858. 87		1160 .00	1072 .00	617. 89	1072 .00	1127 .00	784. 86	588. 06	1375 .00	1200 .00	1104 .00

F		0																				
GR O- alp ha		891 .96	711.4 0	826. 88	853. 52	812. 76	800. 86	881. 89	839. 69	698. 36	753. 30		870. 61	673. 11	660. 92	886. 37	666. 36	739. 51	764. 45	715. 28	842. 00	698. 36
HG F		203 5.0 0	4662. 00	3798 .00	2626 .00	1846 .00	3048 .00	2415 .00	3405 .00	3613 .00	3202 .00		2716 .00	1696 .00	2560 .00	2448 .00	2258 .00	2009 .00	1471 .00	1598 .00	2997 .00	1087 .00
IL- lal pha		49. 40	101.0 5	153. 15	109. 19	63.7 7	154. 77	235. 70	172. 63	198. 56	107. 56		174. 26	161. 27	135. 25	214. 73	237. 32	112. 45	159. 65	111. 64	140. 13	127. 11
IL- 3		2.0 3	1.76	1.76	2.22	1.40	1.94	2.36	1.67	2.12	1.49		1.85	1.31	1.31	2.17	1.76	1.40	1.76	1.67	1.80	1.22
SC F		57. 56	59.15	81.8 1	86.5 5	51.1 7	60.3 5	81.4 1	62.3 4	51.5 7	79.0 3		71.8 9	57.1 6	51.1 7	110. 54	59.9 5	58.3 6	75.8 6	55.5 6	71.8 9	46.3 8
TR AIL		126 .73	178.0 0	107. 76	147. 75	203. 47	178. 78	137. 88	112. 03	149. 72	124. 73		159. 23	84.5 9	128. 93	171. 70	92.3 3	195. 00	134. 21	133. 51	147. 56	208. 28
M- CS F		20. 05	61.08	41.2 3	40.7 7	22.1 4	32.7 4	33.8 1	43.1 8	33.1 2	39.7 2		43.3 3	34.8 7	31.8 3	40.0 2	34.5 7	24.3 9	32.7 4	26.0 1	35.2 5	23.6 1
CT AC K		55. 33	75.58	63.6 3	68.7 7	53.5 8	86.0 3	89.3 8	80.6 5	92.0 5	110. 28		78.2 9	61.5 6	80.6 5	102. 02	87.0 4	69.8 0	66.3 8	77.2 7	73.2 0	71.1 6
IL- 15		512 .08	285.3 6	402. 31	466. 42	349. 32	564. 70	637. 35	520. 26	580. 62	428. 23		544. 62	445. 30	238. 17	617. 96	662. 31	406. 66	371. 59	458. 00	445. 30	578. 64
IL- 7		35. 36	37.65	43.0 7	42.6 3	48.8 1	59.7 1	60.7 6	51.6 3	59.9 2	64.7 0		62.6 3	39.9 3	44.1 9	84.4 4	58.6 6	59.0 8	36.2 8	54.0 0	48.3 8	64.4 9
IL- 12p 70		4.6 3	3.89	4.89	4.63	4.38	6.20	7.56	6.06	6.73	6.46		6.46	6.20	4.26	8.11	7.83	5.15	4.63	6.46	4.76	7.83
IL- 17		24. 55	29.05	32.4 4	35.0 7	29.0 5	39.9 8	43.0 0	36.2 1	46.2 2	39.2 2		41.1 1	30.5 5	27.9 2	62.2 9	35.0 7	38.4 7	32.2 5	43.0 0	36.9 6	51.1 3
IL-		293	257.0	245.	218.	268.	259.	253.	232.	203.	228.		253.	173.	210.	227.	148.	248.	167.	243.	258.	241.



**Supplementary Table 4. Key Resources (reagents)**

REAGENT	SOURCE	Catalog #	RRID
rabbit monoclonal anti-MPO antibody	Abcam	ab208670	AB_2864724
rabbit monoclonal anti- $\alpha$ SMA antibody	Abcam	ab124964	AB_11129103
rabbit monoclonal anti-TIPM-1 antibody	Abcam	ab211926	AB_3095674
rabbit monoclonal anti-COL1A1 antibody	Abcam	ab138492	AB_2861258
rabbit monoclonal anti-RAS antibody	Cell Signaling Technology	91054	AB_3697442
rabbit monoclonal anti-bRAF antibody	Cell Signaling Technology	9433	AB_2259354
rabbit monoclonal anti- phospho-bRAF antibody	Cell Signaling Technology	2696	AB_390721
rabbit monoclonal anti-cRAF antibody	Cell Signaling Technology	12552	AB_2728706
rabbit monoclonal anti- phospho-cRAF antibody	Cell Signaling Technology	9421	AB_330759
rabbit monoclonal anti-MEK antibody	Cell Signaling Technology	8727	AB_10829473
rabbit monoclonal anti- phospho-MEK antibody	Cell Signaling Technology	9154	AB_2138017
rabbit monoclonal anti-JNK antibody	Cell Signaling Technology	9252	AB_2250373
rabbit monoclonal anti- phospho-JNK antibody	Cell Signaling Technology	4668	AB_823588
rabbit monoclonal anti-ERK antibody	Cell Signaling Technology	4695	AB_390779
rabbit monoclonal anti- phospho-ERK antibody	Cell Signaling Technology	4370	AB_2315112
rabbit monoclonal anti-p38 antibody	Cell Signaling Technology	8690	AB_10999090
rabbit monoclonal anti- phospho-p38 antibody	Cell Signaling Technology	4511	AB_2139682
rabbit monoclonal anti-GAPDH antibody	Cell Signaling Technology	2118	AB_561053
mouse monoclonal anti-GAPDH antibody	Cell Signaling Technology	97166	AB_2756824

rabbit monoclonal anti-TAOK1 antibody	Thermo Fisher Scientific	PA5-101868	AB_2851300
Mouse monoclonal anti-MAPKAPK5 antibody	Thermo Fisher Scientific	H00008550-M02	AB_10718167
mouse monoclonal anti-MPO antibody	Abcam	ab90810	AB_2146325
rabbit monoclonal anti-H3cit antibody	Abcam	ab5103	AB_304752
Rhodamine Red-X (RRX) goat anti-mouse IgG (H+L)	Jackson	115-295-146	AB_2338766
FITC-AffiniPure goat anti-rabbit IgG (H+L)	Jackson	111-095-003	AB_2337972
APC Cyanine7conjugated anti-mouse CD45(clone 30F11)	Biolegend	103115	AB_312980
PEvio770 conjugate anti-mouse CD11b (clone M1/70)	Thermo Fisher Scientific	12-0112-82	AB_2734869
APC conjugated anti-mouse F4/80 (clone BM8)	Thermo Fisher Scientific	14-4801-82	AB_467558
FITC-conjugated anti-mouse Ly6C (clone AL21)	BD Biosciences	553104	AB_394628
PE-conjugated anti-mouse Ly6G (clone)	Thermo Fisher Scientific	12-9668-82	AB_2572720
Alexa Fluor® 488 monoclonal anti-rabbit PAD4	Abcam	ab321855	AB_3714924
APC conjugated anti-mouse CD45 (clone I3/2.3)	Biolegend	147707	AB_2563539
PE-conjugated anti-mouse Ly6G (clone 1A8)	Biolegend	127607	AB_1186104
PerCP/Cyanine5.5 anti-mouse CD11b (M1/70)	Biolegend	101227	AB_893233
IL-8	Sigma-Aldrich	I1645	N/A
G-CSF	Sigma-Aldrich	SRP3263	N/A
TNF-beta	Sigma-Aldrich	T7799	N/A
Myeloperoxidase Inhibitor PF1355	Cayman Chemical	1435467-38-1	N/A
ELANE Inhibitor	Cayman Chemical	201677-61-4	N/A

ONO5046			
DNase I	Sigma-Aldrich	AMPD1	N/A
TAO Kinase inhibitor 1	MedChemexpress	HY-112136	N/A
MAPK Inhibitor U0126	Sigma-Aldrich	1173097-76-1	N/A